Dabigatran versus warfarin in patients with atrial fibrillation.
- S. Connolly, M. Ezekowitz, L. Wallentin
- MedicineNew England Journal of Medicine
- 10 December 2009
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
- S. Connolly, M. Gent, B. O'brien
- MedicineCirculation
- 21 March 2000
A 20% relative risk reduction occurred in all-cause mortality and a 33% reduction occur in arrhythmic mortality with ICD therapy compared with amiodarone; this reduction did not reach statistical significance.
Effect of dronedarone on cardiovascular events in atrial fibrillation.
- S. Hohnloser, H. Crijns, S. Connolly
- MedicineNew England Journal of Medicine
- 10 December 2009
Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation and had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash and an increased serum creatinine level than the placebo group.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- J. Eikelboom, S. Connolly, S. Yusuf
- MedicineNew England Journal of Medicine
- 27 August 2017
Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Cardiac-resynchronization therapy for mild-to-moderate heart failure.
- A. Tang, G. Wells, J. Rouleau
- MedicineNew England Journal of Medicine
- 15 December 2010
Among patients with NYHA class II or III heart failure, a wide QRS complex, and left ventricular systolic dysfunction, the addition of CRT to an ICD reduced rates of death and hospitalization for heart failure.
Apixaban in patients with atrial fibrillation.
- S. Connolly, J. Eikelboom, S. Yusuf
- MedicineNew England Journal of Medicine
- 2 March 2011
In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
- S. Hohnloser, K. Kuck, S. Connolly
- MedicineNew England Journal of Medicine
- 9 December 2004
Prophylactic ICD therapy does not reduce overall mortality in high-risk patients who have recently had a myocardial infarction, and is associated with a reduction in the rate of death due to arrhythmia, that was offset by an increase in the rates of death from nonarrhythmic causes.
Embolic strokes of undetermined source: the case for a new clinical construct
- R. Hart, H. Diener, S. Connolly
- MedicineLancet Neurology
- 1 April 2014
Subclinical atrial fibrillation and the risk of stroke.
- J. Healey, S. Connolly, S. Hohnloser
- MedicineNew England Journal of Medicine
- 11 January 2012
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism.
Newly identified events in the RE-LY trial.
- S. Connolly, M. Ezekowitz, S. Yusuf, P. Reilly, L. Wallentin
- MedicineNew England Journal of Medicine
- 3 November 2010
After discussions with the Food and Drug Administration, the primary and secondary efficacy and safety data were checked for consistency, and the study database was reevaluated for possible underreporting of events.
...
...